Allarity Therapeutics expands in-house lab to add proteomics, cell line research
Bitget2026/09/28 12:04- Allarity Therapeutics expanded its in-house medical laboratory to add proteomics and cell line research capabilities.
- Build-out targets deeper mechanism-of-action work on lead asset stenoparib, a dual PARP and WNT pathway inhibitor in Phase 2.
- New services broaden the lab’s external offering, adding to existing transcriptomics research and CLIA clinical testing.
- nCounter Pro platform now supports proteomics via the Human Tumor Signaling Protein Panel, measuring about 300 protein targets.
- Expansion is not expected to change cash runway, with management pointing to cost efficiencies from bringing more research in-house.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The British Pound rallies on a UK growth upgrade and gives more than half back
Only twice in history! S&P 500 equal-weight index is expected to record seven consecutive weeks of decline this week
The S&P 500 Equal Weight Index is expected to fall for a seventh consecutive week. If this downward trend continues through Friday, it will mark only the third time in history that the index has experienced seven straight weeks of decline.
Trump “bites” Powell, demanding his resignation from the Federal Reserve Board, citing severe cost overruns in headquarters renovation.
U.S. President Trump on Wednesday called for former Federal Reserve Chairman Powell to resign from his position as a Fed governor, following an inspector general report on the Federal Reserve headquarters renovation project, which highlighted a series of management issues that led to significant cost overruns.
Crypto prices
More
